Clinical Trial Update: Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating clobetasol propionate ophthalmic nanoemulsion 0.05% for inflammation after cataract surgery in infants is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infantile Cataract

Drugs mentioned

• Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% (clobetasol propionate)

Snippet

Sponsor: Salvat | Conditions: Cataracts Infantile | Phase 3 | Status: RECRUITING